Orforglipron Significantly Lowers HbA1c in Two Additional T2D Trials
Topline data from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes, have been announced.
The ACHIEVE-2 trial compared the efficacy and safety of orforglipron with dapagliflozin in adults with T2D and inadequate glycemic control with metformin.
- 962 study participants with a baseline hemoglobin A1c (HbA1c) of 8.1% were randomly assigned to receive orforglipron (3mg, 12mg, or 36mg) or dapagliflozin (10mg) once daily, alongside background metformin therapy.
- The primary endpoint was the change from baseline to week 40 in HbA1c.
Author's summary: Orforglipron lowers HbA1c in T2D trials.